New 'Living Drug' trial targets tough cancers with engineered immune cells
NCT ID NCT06821048
Summary
This is an early-stage study testing the safety of a new type of CAR-T cell therapy called PTC13 in adults with advanced solid tumors that have a marker called CEA. The therapy involves collecting a patient's own immune cells, genetically engineering them in a lab to better target cancer, and then infusing them back into the abdomen. The main goal is to find a safe dose and see how well the body tolerates the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
RECRUITINGHangzhou, Zhejiang, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.